This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Studer, U. E. Articles by Collette, L. Search for Related Content PubMed PubMed Citation Articles by Studer, U. E. Articles by Collette, L. Related Articles Related Correspondence

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Urs E. Studer, Peter Whelan, Walter Albrecht, Jacques Casselman, Theo de Reijke, Dieter Hauri, Wolfgang Loidl, Santiago Isorna, Subramanian K. Sundaram, Muriel Debois, Laurence Collette

From the Department of Urology, University Hospital of Bern; Department of Urology, University Hospital of Zurich, Switzerland; Department of Urology, St James' Hospital, Leeds; Department of Urology, Pinderfields Hospital, Wakefield, United Kingdom; Department of Urology, Rudolfstiftung, Vienna; Department of Urology, Krankenhaus Barmherzige Schwestern, Linz, Austria; Department of Urology, Academisch Medisch Centrum, Amsterdam, the Netherlands; Department of Urology, Hospital Nuestra Senora Del Pino, Las Palmas, Spain; Department of Urology, Damiaan Ziekenhuis, Oostende; European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium; and the European Organisation for Research and Treatment of Cancer Genitourinary Group

Address reprint requests to Urs E. Studer, Department of Urology, University Hospital of Bern, 3010 Bern, Switzerland; e-mail: urs.studer{at}insel.ch

PURPOSE: This study (EORTC 30891) attempted to demonstrate equivalent overall survival in patients with localized prostate cancer not suitable for local curative treatment treated with immediate or deferred androgen ablation.

PATIENTS AND METHODS: We randomly assigned 985 patients with newly diagnosed prostate cancer T0-4 N0-2 M0 to receive androgen deprivation either immediately (n = 493) or on symptomatic disease progression or occurrence of serious complications (n = 492).

RESULTS: Baseline characteristics were well balanced in the two groups. Median age was 73 years (range, 52 to 81). At a median follow-up of 7.8 years, 541 of 985 patients had died, mostly of prostate cancer (n = 193) or cardiovascular disease (n = 185). The overall survival hazard ratio was 1.25 (95% CI, 1.05 to 1.48; noninferiority P > .1) favoring immediate treatment, seemingly due to fewer deaths of nonprostatic cancer causes (P = .06). The time from randomization to progression of hormone refractory disease did not differ significantly, nor did prostate-cancer specific survival. The median time to the start of deferred treatment after study entry was 7 years. In this group 126 patients (25.6%) died without ever needing treatment (44% of the deaths in this arm).

CONCLUSION: Immediate androgen deprivation resulted in a modest but statistically significant increase in overall survival but no significant difference in prostate cancer mortality or symptom-free survival. This must be weighed on an individual basis against the adverse effects of life-long androgen deprivation, which may be avoided in a substantial number of patients with a deferred treatment policy.

Supported by Grants No. 5U10-CA11488-19 through 5U10 CA11488-35 from the National Cancer Institute, Bethesda, MD. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute. Buserelin was in part supplied free by the Hoechst Company (now Sanofi-Aventis).

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Early Treatment Gets the Benefit
  James L. Gulley, Howard L. Parnes, John Wright, and William L. Dahut
  JCO 2006 24: 5172-5173 [Full Text]

This article has been cited by other articles:

				G. L. Lu-Yao, P. C. Albertsen, D. F. Moore, W. Shih, Y. Lin, R. S. DiPaola, and S.-L. Yao Survival Following Primary Androgen Deprivation Therapy Among Men With Localized Prostate Cancer JAMA, July 9, 2008; 300(2): 173 - 181. [Abstract] [Full Text] [PDF]

				E. S. Antonarakis, A. L. Blackford, E. Garrett-Mayer, and M. A. Eisenberger Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review J. Clin. Oncol., November 1, 2007; 25(31): 4998 - 5008. [Abstract] [Full Text] [PDF]

				F. Shimizu, A. Igarashi, T. Fukuda, Y. Kawachi, S. Minowada, Y. Ohashi, and M. Fujime Decision Analyses in Consideration of Treatment Strategies for Patients with Biochemical Failure After Curative Therapy on Clinically Localized Prostate Cancer in the Prostate-Specific Antigen Era Jpn. J. Clin. Oncol., October 22, 2007; (2007) hym105v1. [Abstract] [Full Text] [PDF]

				D. A. Loblaw, K. S. Virgo, R. Nam, M. R. Somerfield, E. Ben-Josef, D. S. Mendelson, R. Middleton, S. A. Sharp, T. J. Smith, J. Talcott, et al. Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline J. Clin. Oncol., April 20, 2007; 25(12): 1596 - 1605. [Abstract] [Full Text] [PDF]

				F. H Schroder Early versus delayed endocrine therapy for prostate cancer Endocr. Relat. Cancer, March 1, 2007; 14(1): 1 - 11. [Abstract] [Full Text] [PDF]

				J. L. Gulley, H. L. Parnes, J. Wright, and W. L. Dahut Early Treatment Gets the Benefit J. Clin. Oncol., November 10, 2006; 24(32): 5172 - 5173. [Full Text] [PDF]

				U. E. Studer and C. Laurence In Reply J. Clin. Oncol., November 10, 2006; 24(32): 5173 - 5173. [Full Text] [PDF]